NIR Fluorescence Imaging During Neck Dissection in Head and Neck Cancer Patients After iv Injection of ICG
Conditions
Head and Neck Cancer
Conditions: official terms
Head and Neck Neoplasms
Conditions: Keywords
lymph nodes
Study Type
Interventional
Study Phase
Phase 2
Study Design
Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Intervention
Name: Indocyanine Green
Type: Drug
Overall Status
Recruiting
Summary
The purpose of this study is to determine if NIR fluorescent imaging is an effective approach to detect the margins of head and neck tumours or lymph nodes draining the tumour
Detailed Description
Primary objective:

definition of the distribution of intravenously injected ICG in the normal and pathological lymph nodes draining the dissected tumor in head and neck cancer patients or in nodes recurrences in head and neck cancer

Secondary objectives:

- Evaluation of the ability of NIR fluorescence imaging to determine the tumoral volume, specifically the margins of the tumoral tissues (in the operating room and in the pathology department)

- Analysis of the correlation between ICG fluorescence and tumoral invasion in the dissected lymph nodes
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- All patients requiring neck dissection with or without resection of the primary (the decision and the type of neck dissection are preliminary decided during head and neck multidisciplinary oncologic consultation).

- Informed consent form signed.

Exclusion Criteria:

- Age less than18 years old.

- Inability to give informed consent.

- History of allergy or hypersensitivity against the investigational product (its active substance or ingredients), to iodine or to shellfish.

- Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or disseminated autonomies of the thyroid gland.

- Documented coronary disease.

- Advanced renal impairment (creatinine > 1,5mg/dl).

- During the 2 weeks before the enrolment, concurrent medication which reduces or increases the extinction of ICG (i.e. anticonvulsants, haloperidol and Heparin).

- Pregnancy, breastfeeding
Location
Jules Bordet Institute
Brussels, Belgium
Status: Recruiting
Contact: Antoine Digonnet, MD - 003225413319 - antoine.digonnet@bordet.be
Start Date
December 2013
Completion Date
October 2014
Sponsors
Jules Bordet Institute
Source
Jules Bordet Institute
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page